Elevance Health Inc. operates with a market capitalization of $81.5 billion, positioning the managed care provider with a distinctive valuation profile that systematic screening highlights through its price-to-sales ratio of 0.41. This compressed multiple relative to revenue generation reflects the structural margin characteristics inherent in health insurance operations, where the company posted a net profit margin of 2.47% on trailing twelve-month results.

The fundamental model indicates several quantitative strengths in ELV's current positioning:

• Revenue expansion of 6.27% year-over-year demonstrates organic growth momentum within the managed care segment, driven by membership gains and rate adjustments across commercial and government-sponsored plans
• The debt-to-equity ratio of 0.73 suggests moderate financial leverage, providing capacity for strategic capital deployment while maintaining investment-grade characteristics
• A beta coefficient of 0.7 indicates lower volatility relative to broader equity indices, appealing to systematic screens prioritizing defensive healthcare exposure
• Return on equity of 11.24% reflects reasonable capital efficiency within the capital-intensive insurance model

Risk factors emerge from the current ratio of 0.19, reflecting the asset-liability timing dynamics typical of insurance operations but warranting liquidity monitoring. The EPS contraction of -4.24% year-over-year flags margin pressure from medical cost trends and regulatory factors affecting the sector broadly.

Trading at $375.84 with a P/E ratio of 16.59, quantitative screening positions ELV alongside peers UNH, HUM, and CNC within the managed care universe, with the valuation framework suggesting sector-relative pricing dynamics that research perspectives analyze through claims cost trajectories and enrollment mix shifts.